drugset / Trial / NCT05396937

Efficacy and Safety of T+A+RAD in HCC

NCT05396937 ↗

Phase 2 Unknown 42 enrolled Fudan University Roche Pharma AG · collab
NaSingle-groupOpen-labelTreatment

Summary

This is An Open-label, Single-arm Exploratory Study to determine the efficacy and safety of Multifocal Stereotactic Radiotherapy Combined with Atezolizumab and Bevacizumab in the Treatment of Metastatic Hepatocellular Carcinoma

Timeline

Start
2022-01-12
Primary completion
2023-12
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody 1200 mg Intravenous
Subject Bevacizumab Monoclonal antibody 10 mg/kg Intravenous